IRVINE, Calif., Jan. 14, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced it has partnered with Dacos A/S ("Dacos"), a high-tech production company of life sciences products with headquarters in Denmark, to deliver end-to-end temperature-controlled logistics solutions to Dacos' global client base of biopharmaceutical companies.
Dacos is a leading manufacturer of laboratory products for the storage of biological commodities, including human and animal cells, specializing in the production of high-quality cryogenic vials, storage boxes, centrifuge tubes, shipment containers for blood samples and PET bottles for serum and media. Partnering with Cryoport will enable Dacos to offer Cryoport's full range of temperature-controlled logistics solutions, including the Cryoport Express® shippers, the industry-leading Cryoportal™ Logistics Management Platform, Smartpak II™ Condition Monitoring System and 24/7/365 logistics support, to its existing client base of biopharmaceutical companies.
Max Terpager, Chief Executive Officer at Dacos, said, "We have clients all over the world and many of them require reliable, secure logistics solutions for their temperature-sensitive commodities, in order to minimize the risks of temperature excursions that may impact the quality of their products. We receive requests for these solutions on a daily basis, but until now we have never had the correct solution to offer them. Cryoport's full suite of logistics solutions, which encompasses full Chain of Custody, Chain of Condition and Chain of Compliance™ traceability, offers a secure, temperature-controlled solution to track and maintain the integrity of temperature-sensitive products. We are pleased to now have the opportunity to fulfill the needs of our client base by offering Cryoport's solution to ensure that products are handled correctly during transportation, backed up by data and non-stop monitoring, so that our clients can take a more proactive approach to managing their supply chain."
Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "Dacos is a highly innovative, reputable company with a global client base. Forming this relationship with Dacos will give us the opportunity to provide Dacos' clients with our sophisticated and proven temperature-controlled logistics solutions at a time when the global need for these solutions is rapidly growing. Our unparalleled expertise in life sciences logistics allows biopharmaceutical companies to rely on an intelligent, technology-driven solution to mitigate supply chain risks. We see the need for our solutions growing as the regenerative therapy market continues to advance and higher numbers of samples are sent around the world."
About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to: simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting; delivering the most advanced temperature-controlled logistics solutions for the life sciences industry; and providing vital information that provides peace of mind throughout the life of each logistics process.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2017 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE Cryoport, Inc.